Latest News & Features
Pharma
Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers. 27 August 2026
Regulation & Industry
Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices. 27 August 2026
Biotech
As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler 27 August 2026
Careers
The new practice head has represented life sciences clients in numerous high-profile disputes, and will be an “invaluable resource for our clients”, according to the firm. 26 August 2026
Regulation & Industry
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal. 25 August 2026
Regulation & Industry
Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government. 24 August 2026
Careers
The four-person team adds significant life sciences experience to the litigation boutique, drawn to move firms by Stris’ “outstanding trial lawyers” and “sophisticated appellate capabilities”. 24 August 2026
Pharma
Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis. 21 August 2026
Biotech
Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings. 20 August 2026
Pharma
A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products. 20 August 2026